Elicio Therapeutics, Inc. (ELTX): Entry into a Material Definitive Agreement
Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 tm2619637d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 1, 2026, between Elicio Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified
How this was made
The 30-second read
Why it matters
The disclosed per-share purchase price ($3.43) and inclusion of pre-funded warrants signal a structured equity raise that can affect valuation via dilution and warrant economics, while also potentially addressing near-term funding needs.
Market read
This is a fresh primary disclosure of a financing agreement, which can drive trading decisions around dilution risk and expected closing timing.
What to watch
Traders will need the missing parts of the 8-K/exhibit (total shares, gross proceeds, closing conditions, use of proceeds, and any investor concentration) to judge whether the financing is supportive or dilutive enough to drive a sustained move.
Background
The filing is an SEC Form 8-K reporting entry into a material definitive agreement, with an exhibit describing a securities purchase agreement dated July 1, 2026.
Ticker impact
Elicio Therapeutics entered a material definitive securities purchase agreement, issuing common stock and pre-funded warrants at $3.43 per share.
Likely near-term volatility around dilution/financing overhang; direction depends on total raise size and use of proceeds (not shown in excerpt).
This is a primary SEC filing (8-K with exhibit) indicating a fresh capital raise, but the provided text excerpt does not include gross proceeds, share count, or closing terms beyond the per-share price.
Market effects
Small-cap biotech/therapeutics financing conditions may remain sensitive to equity issuance terms and warrant structures.
No clear regional spillover indicated beyond US small-cap risk appetite.
Limited global relevance; primarily company-specific capital structure impact.
Counterpoint
If the financing extends runway or funds de-risking milestones, the warrant overhang may be less negative than typical dilution fears.
Key entities
- CompanyElicio Therapeutics, Inc.
Subject of the 8-K; entered a securities purchase agreement for issuance of common stock and pre-funded warrants.
- Placement agentTitan Partners Group LLC (division of American Capital Partners, LLC)
Named as lead placement agent in the securities purchase agreement.
